Pulmonx Stock

Pulmonx FCF Margin

The Free Cash Flow Margin of Pulmonx (LUNG) as of Aug 12, 2026 is -36.35 %. In the previous year, Free Cash Flow Margin was -39.37 % — a change of -7.65% (higher).

FCF Margin

-36.35 %

YoY

-7.65%

Last updated:

Free Cash Flow Margin of Pulmonx is 2026 -36.35 % . Free Cash Flow Margin of Pulmonx was 2025 -39.37 % . It decreases by -7.65% higher compared to the previous year.
Access this data via the Eulerpool API

Pulmonx Stock analysis

What does Pulmonx do? Pulmonx Corp is an innovative medical technology company based in the USA and Europe. The company specializes in the development of non-invasive solutions for the treatment of lung diseases. Pulmonx was founded in 1997 and has since introduced numerous groundbreaking technologies to the market that improve the quality of life for patients with chronic lung diseases. Pulmonx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pulmonx stock

Free Cash Flow Margin of Pulmonx is -36.35 % in 2026.

Free Cash Flow Margin of Pulmonx changed from -39.37 % to -36.35 %, representing a -7.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Pulmonx since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Pulmonx with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

Margins — Pulmonx

All Key Metrics — Pulmonx